Answers are grounded in this paper and cite their sources.
Background Migraine is a highly prevalent neurological disorder and a leading cause of disability worldwide. Despite the availability of effective preventive therapies, many individuals with disabling migraine remain underdiagnosed or undertreated, particularly in primary care. Patient-reported outcome measures (PROMs) can help capture disease burden directly from patients and support early clinical stratification. We aimed to develop and validate MIGRAGILE, a brief 11-item digital self-administered PROM designed to identify, in primary care, patients who are likely to have disabling migraine and to support structured referral decisions to specialised care. Methods We conducted a multicentre study across 20 primary care centres and one tertiary hospital in Spain. MIGRAGILE was developed through systematic literature review, multidisciplinary expert consensus, and direct patient input during development and face-validity assessment, followed by pilot testing and psychometric validation. Content validity was assessed using the Hambleton–Rovinelli item–domain congruence procedure and complementary I-CVI and S-CVI/Ave calculations based on expert ratings of relevance and clarity; face validity was evaluated by patients and clinicians. Test-retest reliability (7–14 days) and inter-observer agreement (three neurologists, two advanced practice nurses, one clinical researcher) were evaluated using weighted Cohen’s kappa, Fleiss’ kappa, and intraclass correlation coefficients (ICC). Criterion validity/classification performance was assessed against a headache-specialist ICHD-3 reference diagnosis, blinded to MIGRAGILE results. Classification and referral rules were prespecified and were not selected or optimised using the validation cohort. “Disabling migraine” was used as an operational study term encompassing high-frequency episodic migraine and chronic migraine. Convergent validity was examined using HIT-6, and associations with care pathways and first-visit management decisions were analysed. Results Of 300 participants, 277 had complete data for the classification performance analysis. MIGRAGILE showed a sensitivity of 93.7% (95% CI 86.8–97.6) and specificity of 94.0% (95% CI 89.4–96.9) for disabling migraine (high-frequency episodic migraine/chronic migraine); the AUC for the binary classification was 0.938. Test–retest reliability was high for monthly headache days (ICC [1, 2] 0.999, 95% CI 0.998–1.000) and monthly disability days (ICC [1, 2] 0.990, 95% CI 0.969–1.000). Agreement was 98.6% for both the algorithm-derived MIGRAGILE classification (κ = 0.966) and referral recommendation (κ = 0.972). For the three-category reason-for-consultation output, overall unweighted Fleiss’ κ was 0.722 (95% bootstrap CI 0.680–0.762). For the ordered five-level referral recommendation, the mean pairwise quadratically weighted Cohen’s κ was 0.666 (95% bootstrap CI 0.615–0.713; range 0.524–0.866). Clinical reference diagnosis was associated with HIT-6 category distribution (χ²(6) = 112.32, p < 0.001; Cramér’s V = 0.45) and care pathways (χ²(6) = 210.79, p < 0.001; Cramér’s V = 0.62). Both treatment-specific comparisons were significant ( p < 0.001). Conclusions MIGRAGILE is a brief digital PROM that showed high classification performance for specialist-diagnosed high-frequency episodic migraine or chronic migraine and generated standardised care-pathway recommendations in primary care. Prospective controlled studies are required to determine whether its use improves referral appropriateness or patient outcomes.
No takes yet. Share an insight, caveat, or question.
Galindo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: